Clinical trials: Lung Cancer, completed
Lung Cancer, Pulmonary Nodule, Solitary
Application of Carbon Dioxide for Identifying the Intersegmental Plane in Thoracoscopic Segmentectomy
With the increasing acceptance of routine computed tomography (CT) screenings, early-stage lung cancer detection is becoming more frequent.
- Conditions
- Lung Cancer, Pulmonary Nodule, Solitary, Segmentectomy, Pulmonary Nodule, Multiple
- Trial name
- NCT05350137
- Testing
- 100% oxygen, Carbon dioxide
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tongji Hospital
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Lung Cancer, Blood Relatives of Patient w/Lung Cancer
Effect of Lung Cancer Diagnoses on Family Behaviors
Background: A health event can be a powerful motivator for abrupt behavior changes. For instance, many people who smoke stop after having a heart attack or being diagnosed with cancer.
- Conditions
- Lung Cancer, Blood Relatives of Patient w/Lung Cancer, Cigarette Smokers
- Trial name
- NCT01862770
- Where
- 2 sites in United States
- Volunteers
- 507 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cancer, Immune Checkpoint Inhibitors
COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival
COVICI-SURV is a nationwide, retrospective observational cohort study using the French national health data system (SNDS) to evaluate whether COVID-19 vaccination, particularly mRNA vaccination, received within 100 days before or…
- Conditions
- Cancer, Immune Checkpoint Inhibitors, COVID-19 Vaccination, Survival
- Trial name
- COVICI-SURV (NCT07729241)
- Where
- France
- Volunteers
- 95,015 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Lung Cancer
Augmented Reality Assisted Lung Nodule Localization: a Multicentered, Prospective, Randomly Controlled, Non-inferiority Trial
With the popularization of CT screening, the detection rate of small lung nodules has greatly increased. Therefore, the clinical thoracoscopic lung nodule biopsy and sub-lobectomy for radical resection of lung cancer are greatly…
- Trial name
- NCT06548451
- Testing
- Augmented reality guided localization
- Where
- 8 sites in China
- Volunteers
- 270 people
- Sponsor
- Shanghai Chest Hospital
Carcinoma, Non Small Cell Lung (NSCLC)
Locally Advanced NSCLC Hyperfractionated RT
This is a prospective phase II study designed to evaluate an accelerated and adaptive RT approach for locally-advanced non-small cell lung cancer (NSCLC).
- Trial name
- ADAPT (NCT03128008)
- Testing
- Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer, Adenocarcinoma
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment
- Conditions
- Non-small Cell Lung Cancer, Adenocarcinoma, Stage IV
- Trial name
- NCT04263090
- Testing
- Rigosertib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Melanoma, Head and Neck Cancer
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck…
- Conditions
- Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT02475213
- Testing
- Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2
- Where
- 20 sites in United States
- Volunteers
- 146 people
- Sponsor
- MacroGenics
Lung Cancer
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have…
- Trial name
- NCT00004151
- Testing
- acridine carboxamide
- Where
- 8 sites in Austria, Denmark and 4 more
- Volunteers
- 15 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005972
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 50 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Non-Small-Cell Lung
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
This non-interventional study will include a representative sample of patients with locally advanced or metastatic NSCLC harboring Epidermal Growth Factor Receptor (EGFR)-mutations in Greece.
- Trial name
- NCT02440854
- Testing
- afatinib
- Where
- 7 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Covid19
Comorbidities and Risk Score in COVID-19 Patients
Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included.
- Trial name
- Comorbidities (NCT04670094)
- Where
- 5 sites in Italy
- Volunteers
- 4,555 people
- Sponsor
- University of Milano Bicocca
Non-Small Cell Lung Cancer
A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
To define the optimal dose of sunitinib when given in combination with rapamycin 2mg. To determine the maximum tolerated dosage of sunitinib and rapamycin given in this fashion.
- Trial name
- SU/Rapamycin (NCT00555256)
- Testing
- sunitinib and rapamycin (Drug will be held)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Lung Cancer Patients
Global, Regional, and National Burdens and Trends of Tracheal, Bronchial, and Lung Cancer in Individuals Aged 70 Years and Older from 1990 to 2021
Despite the increasing health burden of tracheal, bronchial, and lung (TBL) cancer patients aged ≥ 70 years worldwide, data on its burden and trends are limited.
- Trial name
- GDBlung70 (NCT06694194)
- Volunteers
- 111,627 people
- Sponsor
- Hongquan Xing
Carcinoma, Non-Small-Cell Lung
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
- Trial name
- NCT00092001
- Testing
- Sunitinib
- Where
- 14 sites in United States, Italy and 1 more
- Volunteers
- 111 people
- Sponsor
- Pfizer
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib…
- Trial name
- NCT06161051
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or…
- Trial name
- PEARLS (NCT02504372)
- Testing
- Pembrolizumab
- Volunteers
- 1,177 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Carcinoma
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
The purpose of the study is to evaluate the safety and potential benefit of combination amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small cell lung cancer (SCLC) subjects.
- Trial name
- ESCAPE (NCT01357395)
- Testing
- Amuvatinib
- Where
- 12 sites in United States, Poland
- Volunteers
- 23 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.
- Trial name
- MUTACT (NCT01167972)
- Where
- 101 sites in France
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
- Trial name
- NCT00266877
- Testing
- HKI-272
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 172 people
- Sponsor
- Puma Biotechnology, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.